Literature DB >> 27617309

Human papillomaviruses: research priorities for the next decade.

Erika Langsfeld1, Laimonis A Laimins1.   

Abstract

Human papillomaviruses are the causative agents of cervical, anal as well as many oropharyngeal cancers. While prophylactic vaccines have been developed, uptake is low in the US and other Western countries, and access is limited in less developed countries. A number of areas are emerging as critical for future study. These include investigation of the mechanisms regulating infection and progression to cancer at both cervical and oropharyngeal sites as these appear to be distinct. HPV-induced cancers also may be susceptible to immune therapy, revealing opportunities for treating advanced cervical disease and reducing the morbidity of treatments for oropharyngeal cancers. We believe these areas are critical focal points for HPV cancer research in the next decade.

Entities:  

Keywords:  DNA damage; epigenetics; integration; progression; therapeutic vaccines; vaccines

Year:  2016        PMID: 27617309      PMCID: PMC5015772          DOI: 10.1016/j.trecan.2016.04.001

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  37 in total

1.  Methylation status of the E2 binding sites of HPV16 in cervical lesions determined with the Luminex® xMAP™ system.

Authors:  Suzanne Snellenberg; Denise M Schütze; Debbie Claassen-Kramer; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen
Journal:  Virology       Date:  2011-12-02       Impact factor: 3.616

Review 2.  Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?

Authors:  Shafqat Ali Khan; Divya Reddy; Sanjay Gupta
Journal:  World J Biol Chem       Date:  2015-11-26

Review 3.  Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape.

Authors:  Pablo Conesa-Zamora
Journal:  Gynecol Oncol       Date:  2013-08-29       Impact factor: 5.482

4.  CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences.

Authors:  A Thain; O Jenkins; A R Clarke; K Gaston
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

5.  Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype.

Authors:  Cornelia L Trimble; Steven Piantadosi; Patti Gravitt; Brigitte Ronnett; Ellen Pizer; Andrea Elko; Barbara Wilgus; William Yutzy; Richard Daniel; Keerti Shah; Shiwen Peng; Chienfu Hung; Richard Roden; Tzyy Choou Wu; Drew Pardoll
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

6.  The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle.

Authors:  S Duensing; L Y Lee; A Duensing; J Basile; S Piboonniyom; S Gonzalez; C P Crum; K Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

7.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

8.  Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines.

Authors:  Margaret E McLaughlin-Drubin; Donglim Park; Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-17       Impact factor: 11.205

9.  Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia.

Authors:  Lisa Mirabello; Mark Schiffman; Arpita Ghosh; Ana C Rodriguez; Natasa Vasiljevic; Nicolas Wentzensen; Rolando Herrero; Allan Hildesheim; Sholom Wacholder; Dorota Scibior-Bentkowska; Robert D Burk; Attila T Lorincz
Journal:  Int J Cancer       Date:  2012-08-20       Impact factor: 7.396

Review 10.  Human papillomavirus vaccine: safe, effective, underused.

Authors:  Xian Wen Jin; Laura Lipold; Andrea Sikon; Ellen Rome
Journal:  Cleve Clin J Med       Date:  2013-01       Impact factor: 2.321

View more
  9 in total

1.  Human Papillomavirus E7 Oncoprotein Subverts Host Innate Immunity via SUV39H1-Mediated Epigenetic Silencing of Immune Sensor Genes.

Authors:  Irene Lo Cigno; Federica Calati; Cinzia Borgogna; Alessandra Zevini; Silvia Albertini; Licia Martuscelli; Marco De Andrea; John Hiscott; Santo Landolfo; Marisa Gariglio
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

2.  Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer.

Authors:  Prakriti Sen; Pooja Ganguly; Niladri Ganguly
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

Review 3.  The use of rapid and cost-effective blood-based biomarkers in combination with tumour TNM stage for individual head and neck cancer patient treatment selection.

Authors:  Nongnit Laytragoon Lewin; Freddi Lewin; Bengt-Åke Andersson; Sture Löfgren; Lars Erik Rutqvist
Journal:  Med Oncol       Date:  2017-03-18       Impact factor: 3.064

4.  hnRNP L controls HPV16 RNA polyadenylation and splicing in an Akt kinase-dependent manner.

Authors:  Naoko Kajitani; Jacob Glahder; Chengjun Wu; Haoran Yu; Kersti Nilsson; Stefan Schwartz
Journal:  Nucleic Acids Res       Date:  2017-09-19       Impact factor: 16.971

Review 5.  Involvement of Human Papillomaviruses in Cervical Cancer.

Authors:  Xuelian Wang; Xiumin Huang; Youzhong Zhang
Journal:  Front Microbiol       Date:  2018-11-28       Impact factor: 5.640

6.  Enhancement of specific T-lymphocyte responses by monocyte-derived dendritic cells pulsed with E2 protein of human papillomavirus 16 and human p16INK4A.

Authors:  Nuchsupha Sunthamala; Neeranuch Sankla; Jureeporn Chuerduangphui; Piyawut Swangphon; Wanchareeporn Boontun; Supakpong Ngaochaiyaphum; Weerayut Wongjampa; Tipaya Ekalaksananan; Chamsai Pientong
Journal:  PeerJ       Date:  2020-05-20       Impact factor: 2.984

7.  Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers.

Authors:  Tadahiro Honda; Miki Ando; Jun Ando; Midori Ishii; Yumi Sakiyama; Kazuo Ohara; Tokuko Toyota; Manami Ohtaka; Ayako Masuda; Yasuhisa Terao; Mahito Nakanishi; Hiromitsu Nakauchi; Norio Komatsu
Journal:  Mol Ther       Date:  2020-07-09       Impact factor: 11.454

Review 8.  Oncogenic human papillomaviruses.

Authors:  Alison A McBride
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

9.  Human papillomavirus type 16 E6 and E7 oncoproteins interact with the nuclear p53-binding protein 1 in an in vitro reconstructed 3D epithelium: new insights for the virus-induced DNA damage response.

Authors:  Diletta Francesca Squarzanti; Rita Sorrentino; Manuela Miriam Landini; Andrea Chiesa; Sabrina Pinato; Francesca Rocchio; Martina Mattii; Lorenza Penengo; Barbara Azzimonti
Journal:  Virol J       Date:  2018-11-16       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.